On that account, specific targeting of oncogene(s) in individual cancer cell lines, like Her-2/neu in SK-BR-3 and BT-474 cells, or cyclin B1 in MCF-7, could improve breast cancer therapy. Here, ERBB2 is linked to breast carcinoma.